Lääkärikeskus Aava Kamppi
- Address
- Annankatu 32, 00100 Helsinki, Finland
Lääkärikeskus Aava Kamppi - Gastroenterology & Celiac Disease Research
Lääkärikeskus Aava Kamppi is a clinical research facility engaged in advancing therapeutic interventions for chronic gastrointestinal conditions. The center specializes in studying complex immune-mediated digestive disorders and evaluating novel pharmaceutical approaches for patients experiencing persistent symptoms despite standard dietary management.
- Celiac disease symptom management and therapeutic optimization
- Novel pharmacological interventions for gluten-related disorders
- Mucosal healing and symptom assessment in gluten-sensitive enteropathy
The center's research program focuses on improving outcomes for patients with celiac disease who continue to experience symptoms while maintaining a gluten-free diet. Through rigorous clinical trials, the facility evaluates innovative compounds such as ZED1227, assessing their efficacy in addressing persistent gastrointestinal symptoms and promoting mucosal recovery in patients with confirmed intestinal damage.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Dr. Falk Pharma GmbH1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 107 other sites in Finland
Therapeutic Area Benchmark — Finland
Select a therapeutic area to compare against other sites in Finland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Finland
Market Share
Country: Finland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Lääkärikeskus Aava Kamppi
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2/3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP 363856 in the Treatment of Adults with Generalized Anxiety Disorder | Otsuka Pharmaceutical Development & Commercialization Inc. | Phase IV | Not Recruiting | Sep 2023 | Sep 2025 |
IMP list
lock Showing 1 of 3 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Aticaprant | 1 | Unknown | 2024-11-14 | 2024-11-14 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.